Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SSY Group ( (HK:2005) ) has shared an update.
SSY Group has renewed its core commercial arrangements with substantial shareholder Sichuan Kelun for 2026, signing a Master Sale and Purchase Agreement and a Master Products Manufacturing Service Agreement to continue the sale and purchase of materials and the provision of product manufacturing services from 1 January to 31 December 2026. The company has also entered into a new Master Research & Development Services Agreement with the Kelun Group for the same period, formalising R&D collaboration; together these continuing connected transactions fall within the Hong Kong Listing Rules thresholds that require disclosure, reporting and annual review but do not require a shareholder circular or independent shareholders’ approval, underscoring the ongoing operational and strategic integration between SSY Group and one of its key shareholders.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group is a Hong Kong-listed company incorporated in the Cayman Islands, operating in the pharmaceutical sector with a close strategic relationship with Sichuan Kelun, a substantial shareholder holding about 23% of its issued share capital. The group’s operations involve the sale and purchase of materials, product manufacturing services and research and development activities within the broader healthcare and pharmaceutical supply chain.
Average Trading Volume: 8,309,075
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.74B
For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.